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Abstract
Background
Chronic kidney disease (CKD) affects 10–15% of adult population worldwide. Incident
patients on hemodialysis, mainly those on urgent-start dialysis at the emergency room,
have a high mortality risk, which may reflect the absence of nephrology care. A lack of data
exists regarding the influence of baseline factors on the mortality of these patients. The aim
of this study was to evaluate the clinical and laboratory characteristics of this population and
identify risk factors that contribute to their mortality.
Patients and methods
We studied 424 patients who were admitted to our service between 01/2006 and 12/2012
and were followed for 1 year. We analyzed vascular access, risk factors linked to cardiovas-
cular disease (CVD) and mineral and bone disease associated with CKD (CKD-MBD), and
clinical events that occurred during the follow-up period. Factors that influenced patient sur-
vival were evaluated by Cox regression analysis.
Results
The patient mean age was 50 ± 18 years, and 58.7% of them were male. Hypertension was
the main cause of primary CKD (31.8%). Major risk factors were smoking (19.6%), dyslipide-
mia (48.8%), and CVD (41%). Upon admission, most patients had no vascular access for
hemodialysis (89.4%). Biochemical results showed that most patients were anemic with
high C-reactive protein levels, hypocalcemia, hyperphosphatemia, elevated parathyroid hor-
mone and decreased 25-hydroxy vitamin D. At the end of one year, 60 patients died
(14.1%). These patients were significantly older, had a lower percentage of arteriovenous
fistula in one year, and low levels of 25-hydroxy vitamin D.
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Conclusions
The combined evaluation of clinical and biochemical parameters and risk factors revealed
that the mortality in urgent-start dialysis is associated with older age and low levels of vita-
min D deficiency. A lack of a permanent hemodialysis access after one year was also a risk
factor for mortality in this population.
Introduction
In recent decades, chronic kidney disease (CKD) has evolved as a global public health problem
that affects 10–15% of the adult population [1]. Several factors have contributed to this sce-
nario, including the high prevalence of obesity, systemic arterial hypertension (SAH), diabetes
mellitus (DM) and the increased longevity of the population. In 2010, approximately 1.9 mil-
lion patients worldwide were on dialysis [2]. Early diagnosis, better quality of dialysis treat-
ment and the increased number of transplants have decreased the mortality of CKD patients.
The United States Renal Data System (USRDS) showed that the mortality rate associated with
hemodialysis (HD), peritoneal dialysis and transplant patients decreased by 28, 47 and 51%,
respectively, over the past twenty years [2]. However, compared to the general population,
mortality for all cases is 6.1 to 7.8 times greater in dialysis patients, especially during the first
year of therapy, when approximately 22% of patients die [2,3]. Therefore, it is important to
identify risk factors that are associated with CKD and contribute to this high mortality.
Cardiovascular disease (CVD) is one of these factors and is the leading cause of death in
both the general population and in patients with CKD [4]. Declining renal function increases
the prevalence of CVD. Traditional risk factors that contribute to the development of CVD,
such as age, SAH, DM, obesity and dyslipidemia, are more prevalent in patients with CKD
than in subjects with normal renal function [5,6]. In addition, CKD itself is associated with
worse cardiovascular outcomes, such as ventricular hypertrophy [5]. Systemic inflammation
and malnutrition contribute directly to the increased mortality and hospitalizations in patients
with CKD and are mutually dependent [7]. Therefore, markers of nutritional status, such as
serum creatinine, albumin, and cholesterol, are associated with mortality, as are inflammatory
markers such as C-reactive protein (CRP) and interleukin-6 [8]. Disturbances of mineral
metabolism (CKD-MBD) have also been described as risk factors contributing to mortality in
patients with CKD [9] and include disorders in serum calcium (Ca), phosphorus (P), parathy-
roid hormone (PTH), 25-hydroxy vitamin D and fibroblast growth factor 23 (FGF-23) [10].
Finally, an important risk factor for mortality is late referral to a nephrologist [11].
Although current guidelines recommend early referral of patients with CKD to a specialist,
patients are not evaluated by a nephrologist prior to starting dialysis in an emergency service
[12]. Although a higher mortality rate has already been identified in this scenario, it is unclear
whether the above-mentioned factors influence survival when patients begin dialysis under
emergency conditions.
Thus, the aim of the present study was to evaluate the risk factors associated with mortality
in a cohort of incident and urgent-start HD patients. We hypothesized that, besides all factors
associated with high mortality in patients starting dialysis, among those on urgent-start, late
referral to a nephrologist and the absence a permanent vascular access during the first year will
configure as important risk factors for mortality.
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Patients and Methods
Patients
We included all adult patients who were admitted to the emergency room with clinical signs
and symptoms of uremia, biochemical changes and an immediate need for dialysis. These
patients are referring to those with refractory acidosis, hyperkalemia, hypervolemia, and have
started dialysis within 24 hours after admission.
We excluded renal transplant recipients, patients taking vitamin D, those already in a dialy-
sis program, and patients who recovered renal function. Data were prospectively collected,
and patients were asked to participate at the presentation. There was no patient who declined
to participate. Between January 2006 and December 2012, 444 patients with renal failure and
an indication for immediate dialysis were seen at the Emergency Service of the Hospital das
Clinicas da Faculdade de Medicina da Universidade de São Paulo. Twenty patients were
excluded because three were under 18 years of age, four regularly used vitamin D, four were
kidney transplant recipients, three were already on dialysis and six had recovered renal func-
tion. The remaining 424 patients who met the inclusion criteria were included in this study
and were followed for one year.
Clinical parameters such as age, gender, race, etiology of kidney disease, presence and type
of vascular access for dialysis, major comorbidities and regularly used medications were
obtained from the clinical records of the Emergency Services. Events that occurred during the
first year of dialysis were documented, respecting the confidentiality of information. We con-
sidered smokers those patients with a current smoking habitus. Arterial hypertension was con-
sidered the etiology of renal disease based on information gathered from the chart and the use
of antihypertensive medication. On admission, SAH was defined as long-term use of anti-
hypertensive medication or a systolic blood pressure greater than or equal to 140 mmHg and a
diastolic pressure greater than or equal to 90 mmHg, obtained from annotations during the
Hospital admission, including the measurements before hemodialysis sessions.
For the diagnosis of DM, we used information from the medical record, laboratory test
results and the use of medications such as oral hypoglycemic agents and/or insulin.
Patients with total serum cholesterol levels greater than or equal to 200 mg/dL or LDL cho-
lesterol above 100 mg/dL and triglycerides greater than 150 mg/dL or patients who were taking
lipid-lowering drugs were considered dyslipidemic [13,14]. Medical history of dyslipidemia
was also considered for the diagnosis.
Patients with a history of angina, acute myocardial infarction, angioplasty or myocardial
revascularization were considered to have coronary ischemia. Those patients with a history of
stroke or transient ischemic attack or those who had undergone carotid endarterectomy were
classified as having cerebrovascular disease.
When the medical records documented dyspnea, peripheral edema, jugular stasis, hepato-
megaly, lung congestion detected on physical examination or chest X-ray, limitations regard-
ing engagement in physical activities or the use of specific medications, patients were
diagnosed with congestive heart failure (CHF). The diagnosis was not based on one isolate
symptom or sign. Medication recorded in association with CHF included carvedilol and
nitrate plus hydralazine.
Those patients taking antiarrhythmic medications, with electrocardiogram changes of
rhythm and rate, were classified as having cardiac arrhythmia. We considered arrhythmia any
frequent rhythm but bradichardia, tachycardia and isolated extra beats. By antiarrhythmic, we
mean any drug used exclusively to treat rhythm disorder, particularly amiodarone.
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Patients with a history of claudication, ulceration or amputation due to ischemia of the
limbs or those who underwent peripheral revascularization were diagnosed with peripheral
arterial disease (PAD).
Clinical classification of comorbidities was done at the study entry and also confirmed con-
tinuously during the Hospital admission. For the definition of exposures and confounders in
this study, the patients were categorized based on a clinical assessment made by the nephrol-
ogy team, recruiting all the variables mentioned in the previous section as the most important
for the clinical evaluation.
Biochemical determinations
Blood samples were collected before the first HD session. Serum levels of hemoglobin, hemato-
crit, creatinine, albumin, ionized Ca, P, total cholesterol, LDL cholesterol, HDL cholesterol, tri-
glycerides, glucose, iron, ferritin, alkaline phosphatase, and CRP (immunoturbidimetric
method) were determined using routine laboratory techniques. On the same day, serum/
plasma was stored for further analysis of serum intact parathormone (chemiluminescence
immunoassay, Siemens (DPC), Germany), serum 25-hydroxy vitamin D (radioimmunoassay,
DiaSorin, USA), serum intact FGF-23 (ELISA, Kainos, Japan), and plasma N-terminal-pro-
brain natriuretic peptide (NT-pro-BNP) (chemiluminescence immunoassay, Roche,
Switzerland).
Follow-up
Causes of death were obtained from the patients’ death certificates. Patients submitted to kid-
ney transplant were censored at the date of transplantation for survival analysis.
Ethics statement
The study and its consent procedure were approved by our local ethics committee (Comissão
de E´tica para Ana´lise de Projetos de Pesquisa, CAPPesq, HCFMUSP, approval number CAAE:
45163715.4.0000.0068) and all subjects provided written informed consent before
participation.
Statistical analysis
Data was presented as the means ± standard deviations or medians (25th and 75th percentiles)
depending on the skewness and adherence to a normal distribution of the data, as assessed by
Shapiro-Wilk tests. To assess differences between survivors and non-survivors as a function of
continuous dependent variables, independent t-tests or Mann-Whitney U tests were used.
Chi-square contingency tests were performed to verify associations among surviving groups
and outcome category variables analyzed in the study. Confidence intervals for the proportions
using the normal approximation for the Binomial distribution were calculated. Based on the
dependent variables that were significant in previous univariates tests, adjusted Cox regression
of all-cause mortality with the candidate variables (age, sex, DM, DLP, dialysis vascular access,
CHF, vitamin D) was performed and Confidence Intervals for the estimates of effect sizes
(Hazard Ratio) were calculated using Breslow hazard function [15]. Survival plots for the sig-
nificant outcomes related to mortality were also constructed and presented in Fig 1. For all
analysis, a significance level of 5% (p< 0.05) was adopted. Analyses were performed with SPSS
20.0.1 software (SPSS Inc., USA)
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Fig 1. Cox regression-derived adjusted survival curves according to the type of vascular access (A),
and levels of serum 25-hydroxy vitamin D (B). Model was the same stated in Table 3. (A). The continuous
line represents patients with a temporary catheter, the upper dashed line represents patients with an
arteriovenous fistula, and the middle dashed line represents patients with a tunneled catheter. (B). The
continuous line represents patients with 25 hydroxy vitamin D levels > 15 ng/ml, and the dashed line
represents patients with 25 hydroxy vitamin D 15 ng/ml.
doi:10.1371/journal.pone.0167895.g001
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Results
Baseline
Demographic and clinical characteristics of the study population categorized as survivors and
non-survivors are shown in Table 1. Patients were relatively young, and most of them were
men and Caucasian. SAH and DM accounted for more than 60% of the underlying cause of
Table 1. Comparison between survivors and non-survivors.
Survivors N = 364 Non-survivors N = 60 Total N = 424 p
Age (years) 48 ± 17 59 ± 18 50 ± 18 < 0.0001
Race (Caucasian) 251 (69) 42 (70) 293 (69.1) 0.871
Gender (male) 218 (60) 31 (52) 249 (58.7) 0.231
CKD Etiology
Chronic hypertensive nephropathy 117 (32) 18 (30) 135 (31.8) 0.171
Diabetic nephropathy 104 (29) 21 (35) 125 (29.5)
Glomerulonephritis 49 (13) 4 (7) 53 (12.5)
Autosomal dominant polycystic kidney disease 11 (3) 1 (2) 12 (2.8)
Other 83 (23) 16 (27) 99 (23.3)
Risk Factors
Smoking 69 (19) 14 (23) 83 (19.6) 0.428
Dyslipidemia 181 (50) 26 (43) 207 (48.8) 0.359
Congestive Heart Failure 66 (18) 18 (30) 84 (19.8) 0.033
Coronary ischemia 50 (14) 7 (12) 57 (13.4) 0.663
Peripheral artery disease 28 (8) 5 (8) 33 (7.8) 0.864
Arterial hypertension 349 (96) 57 (95) 406 (96) 0.754
Diabetes mellitus 126 (35) 24 (40) 150 (35) 0.419
First vascular access
Temporary catheter 322 (88) 57 (95) 379 (89) 0.313
AVF 15 (4) 1 (2) 16 (4)
Tunneled catheter 27 (7) 2 (3) 29 (7)
Final vascular access
Temporary catheter 8 (2) 10 (17) 18 (4) < 0.0001
AVF 289 (79) 29 (48) 318 (75)
Tunneled catheter 65 (18) 20 (33) 85 (20)
PTFE 2 (1) 1 (2) 3 (1)
Medications at baseline
ACE/ARB 79 (22) 21 (35) 100 (23) 0.025
Beta-blocker 178 (49) 26 (43) 203 (48) 0.424
Calcium antagonist 247 (68) 34 (57) 274 (66) 0.089
Sevelamer 36 (10) 3 (5) 39 (9) 0.225
Medications at the end of follow-up
ACE/ARB 84 (23) 21 (35) 105 (25) 0.047
Beta-blocker 177 (49) 26 (43) 203 (48) 0.447
Calcium antagonist 241 (66) 33 (55) 274 (65) 0.092
Sevelamer 247 (68) 31 (52) 278 (65) 0.014
Follow-up (days) 365 (76; 365) 188 (10; 363) 365 (10; 365) < 0.0001
AVF: arteriovenous fistula; PTFE: polytetrafluoroethylene vascular access. ACE/ARB: angiotensin-converting enzyme inhibitors/angiotensin receptor
blockers Data are expressed as the means ± SD, n (%) or medians (25, 75)
doi:10.1371/journal.pone.0167895.t001
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CKD. The main cardiovascular risk factors were smoking (19.6%); dyslipidemia (48.8%); CHF
(19.8%); coronary ischemia (13.4%) and PAD (7.8%).
On physical examination upon admission, the mean systolic blood pressure was 152 ± 24
mmHg, and the mean diastolic blood pressure was 82 ± 15 mmHg. The majority of patients
had hypertension (95.8%), and 86.8% were taking antihypertensive agents, most notably
calcium channel blockers and beta-blockers. Of note, only 23% of patients were prescribed
angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEs/ARBs). A
considerable proportion of diabetics (32.8%) and individuals with dyslipidemia (48.7%) had
not been treated with specific medications. Most patients had no vascular access on admission
and required a temporary catheter (TC) implant (89.4%). Only 16 patients (3.8%) had an arte-
riovenous fistula (AVF), and were being followed by nephrologist.
Table 2 summarizes the laboratory data of survivors and non-survivors. In 83.7% of patients,
serum hemoglobin was below 11 g/dL, ferritin was less than 100 mg/dL in 10.3%, and the trans-
ferrin saturation rate was less than 20% in 44.5% of patients, using the minimal cut-off preco-
nized by guidelines. Levels below the reference range were found for albumin in 33.5%, total
cholesterol in 70.9%, LDL fraction in 54.8%, and triglycerides in 51.8%. Only 24% of patients
with total cholesterol levels higher than 200 mg/dL were receiving statins (p = 0.064). Most
patients (79.9%) had elevated CRP levels (higher than 5.0 mg/L).
Hypocalcemia and hyperphosphatemia were found in 48.1 and 74.2%, respectively.
Vitamin D was below the reference range (25-hydroxy vitamin D levels < 30 ng/mL) in
95.1%, and secondary hyperparathyroidism (PTH greater than 65 pg/mL) was found in 69.1%
Table 2. Laboratory data at baseline comparing survivors and non-survivors.
Variable Reference Range Survivors n = 364 Non-Survivors n = 60 Total n = 424 p
Creatinine, mg/dL 0.7–1.2 9.1 (6.6; 13.9) 7.8 (6.0; 10.5) 8.8 (6.5; 13.3) 0.014
Urea, mg/dL 10–50 215.5 (176; 275) 190.5 (158; 252) 210 (173; 273) 0.010
Hemoglobin, g/dL 12–17 8.8 (7.7; 10.3) 8.4 (7.6; 9.6) 8.8 (7.7; 10.1) 0.220
Hematocrit, % 37.5–49.5 27.3 (23.6; 31.3) 26.3 (23.9; 29.8) 27.2 (23.8; 31.1) 0.459
Ionized calcium, mg/dL 4.6–5.3 4.44 ± 0.62 4.68 ± 0.46 4.60 (4.2; 4.9) 0.005
Phosphorus, mg/dL 2.7–4.5 7.4 ± 3.5 6.2 ± 1.9 6.7 (5.5; 8.4) 0.011
Alkaline phosphatase, U/L 40–129 88 (70; 124) 100 (77; 134) 90 (71; 128) 0.029
25-OH vitamin D, ng/mL 30–100 12.3 (8; 18) 12.4 (8.0; 15.0) 12.3 (8; 18) 0.346
Parathyroid hormone, pg/mL 10–65 171 (48; 392) 146 (46; 366) 165 (48; 386) 0.484
FGF-23, pg/mL < 53 1,960 (672; 4,303) 1796 (77; 21093) 1,927 (614; 4,212) 0.380
Triglycerides, mg/dL < 150 151 (105; 212) 127 (403; 3821) 147 (103; 207) 0.031
Total cholesterol, mg/dL < 200 177 (146; 205) 156 (129; 211) 175 (145; 205) 0.050
LDL cholesterol, mg/dL < 130 96 (74; 120) 93 (61; 125) 95.5 (73; 121) 0.296
HDL cholesterol, mg/dL > 60 43 (35; 54) 42 (34; 57) 43 (35; 54) 0.965
Albumin, g/dL 3.4–4.8 3.26 ± 0.7 3.17 ± 0.6 3.3 (2.8; 3.7) 0.323
C-reactive protein, mg/L < 5.0 13.6 (5.7; 43.8) 32.2 (8.9; 107.0) 14.9 (5.8; 47.5) 0.012
Glucose, mg/dL 70–99 89 (79; 135) 90 (79; 131) 89 (79; 133) 0.807
Iron, μg/dL 59–158 53 (38; 77) 43 (23; 67) 51 (36; 74) 0.012
Ferritin, ng/dL 30–400 346 (195; 628) 272 (154; 522) 336 (193; 616) 0.102
IBC, % 20–50 22.1 (14.9; 31.1) 19.0 (12.5; 30.1) 21.8 (14.7; 30.7) 0.178
NT-pro-BNP, pg/mL < 100 4,793 (1,061; 14,691) 4,900 (1,194; 15,654) 4,839 (1,078; 14,813) 0.569
IBC: Iron-binding capacity; NT-pro-BNP: N-terminus of the prohormone brain natriuretic peptide. Data are expressed as the means ± standard deviations or
medians (25, 75).
doi:10.1371/journal.pone.0167895.t002
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of patients. FGF-23 levels were normal in 0.47% of patients, with a median of 1927 pg/mL
(19.1 to 37,721 pg/mL).
NT-pro-BNP levels were measured in 399 patients, and only eight patients had serum levels
within the reference range (up to 100 pg/mL). Forty-three percent of patients had levels above
6000 pg/mL, a cut-off value usually observed in CHF patients on dialysis [16]. Among these
patients, CHF was more prevalent than among patients with levels below 6000 pg/mL (47.6%
vs. 36.8%, respectively; p = 0.006).
Follow-up
There was no loss to follow up. At the end of the first year, 60 patients had died (14.1%), and
nine had received a kidney transplant (2.1%) (with a median follow-up time of 188 days).
Twenty-seven patients (45%) died due to infection; twenty-seven patients (45%) died due to
cardiovascular causes, including acute myocardial infarction, stroke and sudden cardiac death.
Other causes such as pulmonary embolism, hypovolemic shock, and suicide accounted for the
remaining causes of death. Patients who died were older, had CHF, and still remained without
AVF. In addition, non-survivors had lower levels of urea, creatinine, total cholesterol, triglyc-
erides and serum iron, while CRP levels were higher (Table 2). Regarding mineral metabolism
markers, we observed that the levels of serum Ca and alkaline phosphatase were higher, while
serum P was lower. In addition, non-survivors had a higher prevalence of serum levels of
25-OH vitamin D lower than 15 ng/mL (81.4% vs. 63.7%, respectively, p = 0.008). The mortal-
ity risk associated with these levels of vitamin D was 1.9 times higher in these patients.
Non-survivors were receiving more ACE/ARB at baseline (35 vs. 22%, p = 0.025) and also
at the end of follow-up (35 vs. 23%, p = 0.047). Non-survivals were also receiving more anti-
platelets drugs (45 vs. 33%, p = 0.029) at baseline, and less phosphate binder sevelamer at the
end of follow-up (52 vs. 68%, p = 0.014) than survivors.
During the first year of HD, there were 112 hospitalizations, and the hospitalization rate
was 264/1000 patients, which was higher among non-survivors (47 [95%CI 38.1–56.6] vs. 23%
[95%CI 15.4–31.0] survivors, p = 0.0001). During the follow-up, these patients had a higher
incidence of vascular access infection and lung infection (91.7% [95%CI 86.9–0.97] vs. 80.8%
[95%CI 73.0–87.7], p = 0.04 and 80% [95%CI 72.0–86.9 vs. 64% [95%CI 55.4–73.2], p = 0.017,
respectively). In addition, patients who died developed CHF (p = 0.033), arrhythmias
(p = 0.008), coronary ischemia (p = 0.018) and PAD (p = 0.026).
To identify factors associated with mortality, we conducted a Cox regression analysis
(Table 3). In the model, we included all significant variables defined as a p-value less than 0.05
Table 3. Cox regression analysis of factors associated with mortality.
Risk factors β SE HR 95% CI p
Lower Upper
Age 0.033 0.008 1.034 1.017 1.051 0.0001
Male gender 0.154 0.267 1.167 0.691 1.969 0.564
Congestive heart failure 0.333 0.297 1.396 0.780 2.497 0.261
Vascular access
Temporary catheter Reference 0.0001
AVF vs. Temporary catheter -1.944 0.373 0.143 0.069 0.298 0.0001
Tunneled catheter vs. Temporary catheter -0.852 0.401 0.457 0.194 0.936 0.034
Diabetes 0.160 0.272 1.173 0.689 1.998 0.557
Vitamin D < 15 ng/ml 0.759 0.339 2.136 1.098 4.156 0.025
doi:10.1371/journal.pone.0167895.t003
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from the univariate analysis in addition to variables that are consider as confounders for mor-
tality, such as age, gender, presence of DM and CHF. Risk factors associated with mortality
within one year included age, CHF, absence of arteriovenous fistula at follow-up, dyslipidemia
and levels of 25-hydroxy vitamin D lower than 15 ng/ml. Fig 1 shows the adjusted mortality
curves derived from the Cox analysis for Vascular access type (Fig 1A) and levels of
25-hydroxy vitamin D (Fig 1B).
Discussion
In this study, we prospectively followed 424 incident patients with CKD stage 5 who started
HD in the emergency service and were followed for one year. The significant findings were
as following: Except for 16 patients with an AVF (3.8%), the majority of patients were not
being followed-up by a nephrologist; SAH and DM accounted for most cases of kidney
disease. Absence of an AVF after one-year follow-up accounted for mortality as well as
indirect evidence of malnutrition (low serum levels of P, cholesterol and 25-hydroxy vita-
min D).
Incident HD patients have high mortality rates [17]. In the current study, the clinical condi-
tions of the patients on admission were of concern because most were hypertensive; had no
definitive vascular access; were anemic; had evidence of abnormal mineral metabolism; were
not adequately treated for DM; and had hypertension, dyslipidemia, high serum CRP levels
and indirect signs of malnutrition. Altogether, this clinical scenario reveals a failure in the pri-
mary health care system. Nonetheless, the mortality rate was still low compared with other
studies [18]. The access to a major complexity hospital and the quality of HD offered during
the follow-up, may explain, at least partially, the observed mortality rate.
Recently, a review by Cochrane Database of Systematic Reviews analyzed the results of 40
studies with 63,887 patients, of whom 43,209 were referred for early follow-up with nephrolo-
gists, and 20,678 were referred at a later stage [19]. The results showed reduced mortality and
hospitalization rates and more patients with vascular access for HD in those with early referrals
to a specialist. In our study, late or no referral to a nephrologist is a plausible explanation to the
absence of HD vascular access, while international records suggest that at least 50% of patients
starting HD should have an AVF. We have demonstrated that having an AVF during the first
year of HD was a protective factor. However, we cannot guarantee that these patients had a TC
placement, even though for a short period of time.
Malas et al. conducted a retrospective study using data from the American Registry Data of
the USRDS in which they evaluated 510,000 patients [20]. Most patients (82.6%) started HD
with a TC, and only 14% of the patients had an AVF. In agreement with our findings, AVF
was associated with a lower mortality rate (23%). An AVF can reduce mortality as it is related
to early referral to nephrologists and vascular surgeon and anatomical conditions for a fistula
creation. On the other hand, our study can be biased due to higher probability of obtaining an
AVF for persons who survive longer, and not necessarily means that having an AVF can
improve survival.
At the end of the one-year follow up, 75% of our patients had an AVF, which has a positive
impact on mortality, primarily compared with a TC. Interestingly, a tunneled catheter was
associated with a survival curve that is not necessarily similar to an AVF. This finding may
reflect either the clinical condition of the patients or the dialysis center to which they were
referred.
Infections related to vascular access are the most common identifiable source of infection
in patients on HD that contributes to increased mortality [21]. In addition to increased mortal-
ity, the direct and indirect costs of hospitalizations are high. In our country, this cost is
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unknown, but data from the literature support a range from 17,000 to 32,000 dollars per
patient [22].
Most of our patients (80%) had hemoglobin levels lower than 11 g/dL. Although we did not
detect an impact of anemia on mortality, this factor is considered a non-traditional risk factor
for the development of CVD and contributes to myocardial hypertrophy and higher mortality
in patients with CKD [23]. We did not detect an impact of lipid disorders either; these disor-
ders are a risk factor that increases the mortality of both the general population and patients
with CKD. The lipid profile of the patients suggests the presence of malnutrition as 50% had
low levels of cholesterol those who did not survive had lower serum triglycerides, urea, creati-
nine, P and iron levels and high serum levels of CRP, all of which are indirect effects of malnu-
trition. Unfortunately, we have no data regarding body weight, height, or body mass index or
information about recent weight loss, dietary recall, gastrointestinal symptoms and functional
capacity to confirm the presence or the absence of malnutrition. However, protein-calorie
malnutrition associated with inflammation has been extensively studied in recent years and is
considered a risk factor that increases the mortality of patients with CKD [24].
Regarding the mineral metabolism disorders that were present in most patients, serum Ca
levels and alkaline phosphatase levels were higher in patients who died, which might reflect
increased bone turnover, whereas the low levels of P reflects malnutrition [25].
Levels of 25-hydroxy vitamin D lower than 15 ng/mL doubled the risk of death indepen-
dently. Vitamin D deficiency is highly prevalent in patients with CKD, particularly in those on
CKD stage 5, and is associated with various clinical outcomes, such as doubling serum creati-
nine levels in patients with kidney disease worsening of anemia, muscle weakness, vascular cal-
cification, endothelial dysfunction and cardiovascular events [26]. Serum levels of 25-hydroxy
vitamin D are influenced by various factors such as seasonality, physical activity, inflamma-
tion, DM and proteinuria, which could not be analyzed in this study. Recently, our group eval-
uated the levels of 25-hydroxy vitamin D in normal subjects during the winter and summer,
and the values were 22 ng/mL and 34 ng/mL, respectively. These values were higher than that
those observed in the patients in this study, which was 12.3 ng/mL. The definition of hypovita-
minosis varies among researches and organizations, and the best cutoff to predict mortality
among patients with CKD is still debatable. We have found that levels lower than 15 ng/ml
could predict mortality, in agreement with other published studies, reinforcing the idea that
vitamin D deficiency increases the risk of death [27]. However, whether vitamin D replace-
ment improves survival in incident patients on HD requires further investigation.
In recent years, many publications have demonstrated that serum levels of FGF-23 are asso-
ciated with increased mortality, renal disease progression and development of CVD. This hor-
mone promotes cardiomyocyte hypertrophy [28]. We found no association between mortality
and FGF-23. Serum levels of FGF-23 were very high in virtually all patients, making it difficult
to detect any difference and decipher its role in factors related to survival.
Non-survivors commonly took the antihypertensive ACE-ARB and antiplatelet agents,
which was probably due to their more severe clinical conditions.
The protective effects of the P binder sevelamer hydrochloride on survival of patients on
dialysis have been previously described and were also observed in our study. In addition to
reducing harmful P levels, sevelamer hydrochloride also lowers cholesterol levels, FGF-23, and
advanced products of glycosylation (AGEs), and reduces Ca overload produced by Ca-based
binders [29]. Sevelamer, however, may be associated with nutritional status or access to a bet-
ter quality health care, instead of being a predictor of survival.
In this study, the life expectancy of patients with CHF was slightly lower than that of
patients who did not have this complication. In the American population, CHF is the leading
cause of hospitalization in patients over 65 years, with an annual incidence of approximately
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one million individuals and a mortality rate of 300,000 patients/year [30]. The association
between CKD and CVD is well established. The interaction between the two systems triggers
pathological processes and accelerates dysfunction in both disorders, which is referred to as
cardiorenal syndrome [31]. As clinical diagnosis was made in retrospect based on patient files,
it is plausible that some information may be lacking from source data available to the assessor,
such as exercise intolerance and chronic obstructive pulmonary disease. Also, fluid retention
may be due to renal failure rather than CHF.
Even without properly analyzing the nutritional status of patients, we can infer that malnu-
trition favors mortality, as evidenced by the protective effect of higher levels of urea and tri-
glycerides. The lowest serum levels of urea and cholesterol were associated with higher
mortality in patients with CHF.
In summary, patients who started dialysis at emergency room, malnourished and who have
no AVF during the first year of dialysis are at higher risk of mortality. Efforts should be made
to early referral to a nephrologist. Vitamin D levels lower than 15 ng/ml in these patients also
predict 1-year mortality. However, whether supplementing such vitamin would decrease the
mortality risk is still unknown.
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